Hematologic Malignancies Program

Study Shows Promising Results for Novel Combination Treatment for Relapsed Multiple Myeloma Patients

Ask the Expert

Get answers to your Multiple myeloma questions.

Note: This is for informational purposes only. Doctors cannot provide a diagnosis or individual treatment advice via e-mail. Please consult your physician about your specific health care concerns.

Please install flash player to see this video.

Cancer Center Virtual Tour

Related Content

A recently published multi-institutional Phase I study initiated and chaired by Dr. Ashraf Badros at the University of Maryland Greenebaum Cancer Center evaluated a new combination of drugs -- bortezomib and vorinostat -- for the treatment of relapsed or refractory multiple myeloma patients. The study was sponsored and funded by National Cancer Institute (NCI). The trial established in a Phase I design the appropriate doses of each drug.

According to Dr. Badros, "The regimen was well-tolerated by the study participants and had promising anti-myeloma activity in relapsed and refractory multiple myeloma patients. This work is the basis of ongoing national and international Phase II and III clinical trials to confirm the overall response of patients."

The study, entitled "Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma," was published in the August 15, 2009, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).

Download the study PDF.

This page was last updated on: September 10, 2009.